BTIG raised the firm’s price target on Glaukos (GKOS) to $116 from $104 and keeps a Buy rating on the shares. The company reported “strong” Q3 as Glaucoma revenue of $110.2M was favorable relative to the firm’s estimate, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Cautious Outlook for Glaukos Amid Regulatory Uncertainty and Valuation Concerns
- Glaukos price target raised to $122 from $120 at Wells Fargo
- Strong Buy Rating for Glaukos Driven by iDose Success and Positive Revenue Projections
- Glaukos’s Strong Growth Prospects: Buy Rating Affirmed Amid Surpassing Sales and Promising Pipeline
- Glaukos Corp. Reports Record Q3 Sales Growth